Update in pharmacological management of coronary no-reflow phenomenon.

@article{Salinas2012UpdateIP,
  title={Update in pharmacological management of coronary no-reflow phenomenon.},
  author={Pablo Salinas and Santiago Jim{\'e}nez-Valero and Ra{\'u}l Moreno and {\'A}ngel S{\'a}nchez-Recalde and Guillermo Galeote and Luis Calvo and Juan Carlos Ruiz-Garc{\'i}a and Seb{\'a}stian Eduardo Carrizo and Gabriel Gustavo Trucco and Jos{\'e} Lu{\'i}s L{\'o}pez-Send{\'o}n},
  journal={Cardiovascular & hematological agents in medicinal chemistry},
  year={2012},
  volume={10 3},
  pages={
          256-64
        }
}
The no-reflow phenomenon (NRP) is defined as the lack of adequate myocardial tissue perfusion despite a patent epicardial coronary artery. The incidence of NRP varies between 2-5% of elective percutaneous coronary interventions (PCI) and 30% in primary PCI. Clinically, it is an independent predictor of myocardial infarction, in-hospital mortality, and long-term mortality. It may be categorized in interventional (after PCI, especially in saphenous venous grafts) or reperfusion NRP (after re… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Effect of Different Methods of Administration of Diltiazem on Clinical Efficacy in Patients with Acute ST-Segment Elevation Myocardial Infarction

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND